Sign in: Staff/Students
The Universities of Liverpool and Manchester have been awarded a £1 million scheme by the MRC (Medical Research Council) to provide clinical research training in Clinical Pharmacology and Therapeutics.
The scheme was launched by the MRC as a result of the Blueprint from the Office of Life Sciences. It allows integration of expertise and technologies across the M62 and, by working with industry partners such as Astra Zeneca and GlaxoSmithkline, will provide ‘without walls’ research training. The programme is based on an established Liverpool-Manchester collaboration, the MRC Centre for Drug Safety Science, which is lead by the University and provides the management framework.
The programme focuses on three-year doctoral training for six clinical fellows divided equally between the universities of Liverpool and Manchester. The programme will utilise the combined academic strengths of the universities to focus on stratified medicines and drug safety in the areas of paediatrics, infectious diseases, and inflammation and repair.
You must be logged in to post a comment.
All recent news
Extending Duo two-factor authentication (2FA) to Canvas
World AIDS Day: Are long-acting HIV therapies the future?
Get involved: Activities and events happening this week
New UK coronavirus measures introduced
Obituary: Dr Stephan Pfaffenzeller
Leading experts in the fields of pharmacology and advanced materials, Prof Andrew Owen and Prof Steve Rannard from @CELTLiverpool discuss their pioneering work into long-acting therapeutics for the treatment of HIV.
Full story ➡️ https://bit.ly/3G5Nc3s
Persistent poverty and/or persistent poor parental mental health affects over four in ten children in UK today, @LivUni-led analysis finds ➡️ https://bit.ly/3xButtM
£1.6m programme led by @MPUoL seeks to understand the very rare, but very serious, condition of blood clotting with low platelets in the general population, in #COVID19 infection & potentially following vaccination ➡️ https://bit.ly/3o5GtR1